AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%
Last update at 2024-04-25T20:00:00Z
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | -391.50000M | -14.00000M | 48.70M | -304.90000M | -177.20000M |
Minority interest | - | - | - | - | - |
Net income | -328.00000M | -29.50000M | 30.60M | -312.00000M | -153.00000M |
Selling general administrative | 372.67M | 468.90M | 355.57M | 343.31M | 358.35M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 288.20M | 581.50M | 541.00M | 329.40M | 385.70M |
Reconciled depreciation | 108.66M | 50.30M | 85.36M | 93.81M | 97.34M |
Ebit | -246.20000M | -47.70000M | 57.70M | -196.60000M | -161.20000M |
Ebitda | -178.30000M | 2.60M | 106.10M | -54.30000M | -93.30000M |
Depreciation and amortization | 67.90M | 50.30M | 48.40M | 142.30M | 67.90M |
Non operating income net other | - | -14.52500M | 12.90M | -9.39700M | -8.67900M |
Operating income | -246.20000M | -47.70000M | 57.70M | -196.60000M | -171.20000M |
Other operating expenses | 1250.40M | 1789.20M | 1381.70M | 1098.50M | 1156.50M |
Interest expense | 12.06M | 18.88M | 21.93M | 21.52M | 11.89M |
Tax provision | -63.49900M | 15.50M | 17.62M | 7.06M | -38.72600M |
Interest income | 1.98M | 0.03M | 0.15M | 1.71M | 1.24M |
Net interest income | -10.07500M | -18.85200M | -21.78200M | -19.80600M | -10.65000M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | -31.50800M | - | 92.40M | 21.78M |
Other items | - | - | - | - | - |
Income tax expense | -63.50000M | 15.50M | 17.60M | 7.10M | -38.70000M |
Total revenue | 1004.20M | 1774.70M | 1435.40M | 901.90M | 990.30M |
Total operating expenses | 534.40M | 596.00M | 487.30M | 526.00M | 551.90M |
Cost of revenue | 716.00M | 1193.20M | 894.40M | 572.50M | 604.60M |
Total other income expense net | -145.30000M | 33.70M | -9.00000M | -108.30000M | -11.00000M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | -328.40500M | -30.10000M | 31.07M | -312.02500M | -138.54300M |
Net income applicable to common shares | -328.40000M | -30.10000M | 30.59M | -314.92500M | -138.54300M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Total assets | 2167.30M | 2399.70M | 2473.10M | 2309.30M | 2451.10M |
Intangible assets | 790.90M | 1110.80M | 1270.80M | 1262.10M | 1335.80M |
Earning assets | - | - | - | - | - |
Other current assets | 241.30M | 373.30M | 451.00M | 238.50M | 221.20M |
Total liab | 605.70M | 714.60M | 801.50M | 694.50M | 659.80M |
Total stockholder equity | 1561.60M | 1685.10M | 1671.60M | 1614.80M | 1791.30M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 143.40M | 190.93M | 222.65M | 142.97M | 105.21M |
Common stock | 7.81M | 6.90M | 6.71M | 6.70M | 5.87M |
Capital stock | 7.81M | 6.90M | 6.71M | 6.70M | 5.87M |
Retained earnings | -1822.92300M | -1511.97600M | -1481.83300M | -1511.07700M | -1197.07800M |
Other liab | 126.40M | 196.70M | 204.00M | 153.82M | 198.69M |
Good will | 595.85M | 520.60M | 680.60M | 671.94M | 700.19M |
Other assets | 981.90M | 465.90M | 653.73M | 7.01M | 8.08M |
Cash | 153.20M | 134.70M | 72.21M | 85.45M | 96.47M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 213.50M | 301.80M | 375.50M | 249.10M | 256.80M |
Current deferred revenue | - | 0.26M | 15.78M | 19.20M | 63.50M |
Net debt | 60.30M | 53.20M | 149.79M | 125.75M | -64.87300M |
Short term debt | 3.10M | 28.58M | 36.18M | 24.40M | 40.69M |
Short long term debt | 36.59M | 14.70M | 24.70M | 9.62M | 37.41M |
Short long term debt total | 213.50M | 187.90M | 222.00M | 211.20M | 31.60M |
Other stockholder equity | 3420.03M | 3220.67M | 3150.95M | 3141.24M | 3002.50M |
Property plant equipment | - | 123.95M | 178.29M | 166.49M | 144.67M |
Total current assets | 394.50M | 823.00M | 523.20M | 324.00M | 317.70M |
Long term investments | 28.05M | 10.73M | 15.73M | 20.75M | 31.23M |
Net tangible assets | 770.70M | 574.30M | 515.95M | 413.86M | -158.92600M |
Short term investments | - | - | -0.01100M | 0.05M | 0.03M |
Net receivables | 148.61M | 265.59M | 302.26M | 157.69M | 161.98M |
Long term debt | 219.47M | 187.90M | 225.83M | 259.86M | 167.15M |
Inventory | 74.06M | 86.50M | 132.34M | 53.43M | 42.30M |
Accounts payable | 67.00M | 82.04M | 100.88M | 62.54M | 47.40M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | -43.32300M | -30.49500M | -4.22500M | -22.07000M | -20.13100M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | 6.90M | 6.71M | 6.70M | 5.87M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | -1511.97600M | -1481.83300M | -1511.07700M | -1197.07800M |
Treasury stock | - | -1.79100M | -1.79100M | -1.79100M | -1.79100M |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 832.24M | 465.90M | 679.10M | 723.20M | 797.60M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 1772.80M | 1576.70M | 1949.90M | 1985.30M | 2133.40M |
Capital lease obligations | 49.49M | 49.90M | 44.05M | 46.49M | 8.90M |
Long term debt total | - | - | - | 263.91M | 172.77M |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | 91.04M | 6.08M | 15.11M | -1.20000M | 0.52M |
Change to liabilities | 0.00000M | -44.57000M | 118.99M | 16.40M | -24.36800M |
Total cashflows from investing activities | - | 35.95M | -18.32700M | -13.27000M | -26.11900M |
Net borrowings | - | -11.43100M | -35.83200M | 99.19M | 47.24M |
Total cash from financing activities | 22.97M | -10.35100M | -35.07600M | 175.25M | 140.91M |
Change to operating activities | - | -29.64000M | 98.70M | -10.38400M | 4.22M |
Net income | -328.40500M | -30.14300M | 30.59M | -314.92500M | -153.04000M |
Change in cash | 18.48M | 62.50M | -13.24100M | -11.02100M | 4.97M |
Begin period cash flow | 134.71M | 72.21M | 85.45M | 96.47M | 91.50M |
End period cash flow | 153.19M | 134.71M | 72.21M | 85.45M | 96.47M |
Total cash from operating activities | -95.18900M | 38.34M | 39.48M | -172.52200M | -109.14100M |
Issuance of capital stock | - | 0.00000M | 0.00000M | 76.06M | 92.50M |
Depreciation | 108.66M | 78.72M | 85.36M | 93.81M | 97.34M |
Other cashflows from investing activities | - | 62.03M | 0.24M | 0.67M | 1.22M |
Dividends paid | - | - | - | - | - |
Change to inventory | 13.66M | 30.68M | -77.64200M | -12.13300M | 4.59M |
Change to account receivables | 128.60M | 5.23M | -150.43700M | 7.38M | 20.40M |
Sale purchase of stock | - | - | - | 76.06M | 93.67M |
Other cashflows from financing activities | 837.08M | 1685.61M | 1108.62M | 487.31M | 83.09M |
Change to netincome | - | 9.29M | 19.91M | 104.76M | 11.04M |
Capital expenditures | 24.58M | 32.16M | 33.68M | 12.74M | 27.86M |
Change receivables | - | 5.23M | -150.43700M | 7.38M | 20.40M |
Cash flows other operating | - | -11.66200M | 11.86M | -68.80200M | -65.28700M |
Exchange rate changes | - | - | - | - | -0.67500M |
Cash and cash equivalents changes | - | 63.94M | -13.92700M | -10.54400M | 4.97M |
Change in working capital | 42.65M | -20.48200M | -97.60900M | -68.80700M | -58.14400M |
Stock based compensation | 18.51M | 13.63M | 8.95M | 13.42M | 21.76M |
Other non cash items | 137.80M | -13.54500M | -3.45000M | 99.66M | 18.07M |
Free cash flow | -119.76700M | 6.18M | 5.79M | -185.26300M | -136.99900M |
Sector: Healthcare Industry: Diagnostics & Research
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
OPK Opko Health Inc |
-0.01 0.81% | 1.22 | - | 64.52 | 1.38 | 0.83 | 1.59 | -14.4942 |
TMO Thermo Fisher Scientific Inc |
-5.66 0.98% | 571.73 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
DHR Danaher Corporation |
-4.61 1.84% | 245.80 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
IDXX IDEXX Laboratories Inc |
-5.02 1.02% | 489.24 | 55.57 | 53.76 | 12.50 | 34.56 | 12.72 | 38.21 |
IQV IQVIA Holdings Inc |
-6.86 2.85% | 233.98 | 37.82 | 19.68 | 2.76 | 7.20 | 3.61 | 17.03 |
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
4400 Biscayne Boulevard, Miami, FL, United States, 33137
Name | Title | Year Born |
---|---|---|
Dr. Phillip Frost Ph.D. | Chairman & CEO | 1936 |
Dr. Jane H. Hsiao M.B.A., MBA, Ph.D. | Vice Chairman & Chief Technical Officer | 1947 |
Mr. Adam E. Logal | Sr. VP, CFO, Chief Accounting Officer & Treasurer | 1978 |
Mr. Steven D. Rubin Esq., J.D. | Exec. VP of Admin. & Director | 1960 |
Dr. Jon R. Cohen M.D. | Advisor | 1955 |
Dr. Elias Adam Zerhouni M.D. | Pres & Vice Chairman | 1951 |
Dr. Arie Gutman | Pres of API | 1954 |
Mr. James DeMarco | Sr. VP of Pharmaceutical Sales | NA |
Dr. Akhtar Ashfaq | Sr. VP of Clinical R&D and Medical Affairs | NA |
Ms. Jane Pine Wood Esq., J.D. | Chief Legal Officer of Bio-Reference Laboratories | 1963 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).